<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:71dad24c-437c-4f0e-a0c6-d6fede8def5d,g:cb184e9a-669f-462f-9d99-55ee5d6e4b73,d:ea2e71bb5fc94cb4adc88cbd9eb39a3d--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sppi-20221102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF80L2ZyYWc6N2M1YTg5ODg4MDQwNDYwOWJmN2ZiZGRiZTQ3NDhlMjcvdGFibGU6ZmFlN2YwNTE3MzJkNDFjZTk5YWI5OWQxY2M2YzM4NzMvdGFibGVyYW5nZTpmYWU3ZjA1MTczMmQ0MWNlOTlhYjk5ZDFjYzZjMzg3M18yLTEtMS0xLTM0OTc0_d35a5005-5cbd-487e-8fb2-f451be926114">false</ix:nonNumeric><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF80L2ZyYWc6N2M1YTg5ODg4MDQwNDYwOWJmN2ZiZGRiZTQ3NDhlMjcvdGFibGU6ZmFlN2YwNTE3MzJkNDFjZTk5YWI5OWQxY2M2YzM4NzMvdGFibGVyYW5nZTpmYWU3ZjA1MTczMmQ0MWNlOTlhYjk5ZDFjYzZjMzg3M18zLTEtMS0xLTM0OTc0_39b7b3c6-4983-4def-8f5b-a0503fdaa1fe">0000831547</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sppi-20221102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000831547</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iea2e71bb5fc94cb4adc88cbd9eb39a3d_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjE4_fd69b0b5-4841-4ec7-a3b4-cc741c52bc4a">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xMDk5NTExNjI5NDIy_abcd3f35-64cc-4a70-8ccb-fb40c319b865">November 2, 2022</ix:nonNumeric> </span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjE5_983c7aa3-742d-461e-b20a-16fe3e3821db">SPECTRUM PHARMACEUTICALS INC</ix:nonNumeric> </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6MDJmZWM3YmY2ZGQ2NDVhOTgyZDU4YTQxM2Y3ODU5Y2QvdGFibGVyYW5nZTowMmZlYzdiZjZkZDY0NWE5ODJkNThhNDEzZjc4NTljZF8wLTAtMS0xLTM0OTc0_b296eb2d-87dc-4b66-8553-e6d9c4c2b8d1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6MDJmZWM3YmY2ZGQ2NDVhOTgyZDU4YTQxM2Y3ODU5Y2QvdGFibGVyYW5nZTowMmZlYzdiZjZkZDY0NWE5ODJkNThhNDEzZjc4NTljZF8wLTEtMS0xLTM0OTc0_a38bf9ad-1995-4e24-98db-1ce864e03e90">001-35006</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6MDJmZWM3YmY2ZGQ2NDVhOTgyZDU4YTQxM2Y3ODU5Y2QvdGFibGVyYW5nZTowMmZlYzdiZjZkZDY0NWE5ODJkNThhNDEzZjc4NTljZF8wLTItMS0xLTM0OTc0_1b5f108f-c38a-462b-9b13-6d294c530a05">93-0979187</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction <br/>of incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission <br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer <br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6NTNiYzkzM2U5ZTdmNDYyNWJkY2RmZWVhYTIyMDllZDMvdGFibGVyYW5nZTo1M2JjOTMzZTllN2Y0NjI1YmRjZGZlZWFhMjIwOWVkM18wLTAtMS0xLTM0OTc0_af7f3b1c-c3a3-4905-b10d-23acc5deb590">Pilot House-Lewis Wharf Atlantic Ave</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6NTNiYzkzM2U5ZTdmNDYyNWJkY2RmZWVhYTIyMDllZDMvdGFibGVyYW5nZTo1M2JjOTMzZTllN2Y0NjI1YmRjZGZlZWFhMjIwOWVkM18wLTEtMS0xLTM0OTc0_2c7bf6f0-fc88-47cf-b4bc-f97e4dd40057">6th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6NTNiYzkzM2U5ZTdmNDYyNWJkY2RmZWVhYTIyMDllZDMvdGFibGVyYW5nZTo1M2JjOTMzZTllN2Y0NjI1YmRjZGZlZWFhMjIwOWVkM18wLTItMS0xLTM0OTc0_91cada4b-6e43-479b-8f16-256e13992910">Boston</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6NTNiYzkzM2U5ZTdmNDYyNWJkY2RmZWVhYTIyMDllZDMvdGFibGVyYW5nZTo1M2JjOTMzZTllN2Y0NjI1YmRjZGZlZWFhMjIwOWVkM18wLTMtMS0xLTM0OTc0_e16ef5b8-96e5-4a3c-a1ac-32cd2655f0d0">MA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6NTNiYzkzM2U5ZTdmNDYyNWJkY2RmZWVhYTIyMDllZDMvdGFibGVyYW5nZTo1M2JjOTMzZTllN2Y0NjI1YmRjZGZlZWFhMjIwOWVkM18wLTQtMS0xLTM0OTc0_fe72c83f-254f-4a74-9e72-5a8afa2b0916">02110</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjIw_a4164983-5ba4-4eb2-9431-019d2a5834bf">617</ix:nonNumeric>) <ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjIx_14a38f39-50e8-44a7-87e5-9ceac379395a">586-3900</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address if changed since last report.)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjI0_9afceb00-dddc-4b67-92ad-fed43e7a8cb8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjIy_275d904a-ac28-409a-8314-e509e9b2d4bc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjIz_3802a7ee-543a-4c91-bdc3-7075ccdbbc86">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjE3_ded23145-e8d2-4933-b6b3-65aea15bceaa">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:6pt;margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6M2ZkMjFlZTY4Nzk0NGQwMDlmYzVlYjQ5ODMxODBiMzkvdGFibGVyYW5nZTozZmQyMWVlNjg3OTQ0ZDAwOWZjNWViNDk4MzE4MGIzOV8xLTAtMS0xLTM0OTc0_403defa7-81ea-4790-8fd8-7f084cd0b302">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6M2ZkMjFlZTY4Nzk0NGQwMDlmYzVlYjQ5ODMxODBiMzkvdGFibGVyYW5nZTozZmQyMWVlNjg3OTQ0ZDAwOWZjNWViNDk4MzE4MGIzOV8xLTEtMS0xLTM0OTc0_c042b258-85c0-419a-a543-a2f163e42c40">SPPI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGFibGU6M2ZkMjFlZTY4Nzk0NGQwMDlmYzVlYjQ5ODMxODBiMzkvdGFibGVyYW5nZTozZmQyMWVlNjg3OTQ0ZDAwOWZjNWViNDk4MzE4MGIzOV8xLTItMS0xLTM0OTc0_f3ef3d7f-0190-47a8-9a18-73acfc01cedb">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).   Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia82ed5bb92d6491fa94fa860628fe670_D20221102-20221102" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmVhMmU3MWJiNWZjOTRjYjRhZGM4OGNiZDllYjM5YTNkL3NlYzplYTJlNzFiYjVmYzk0Y2I0YWRjODhjYmQ5ZWIzOWEzZF8xL2ZyYWc6ZDgwM2M1ZjU0NmVmNGEzZjg4OGJhOWExNWJiM2NmMTIvdGV4dHJlZ2lvbjpkODAzYzVmNTQ2ZWY0YTNmODg4YmE5YTE1YmIzY2YxMl8xNjI1_0ca3f420-eaf6-46ac-8d2c-f3637cafb918">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iea2e71bb5fc94cb4adc88cbd9eb39a3d_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:115%">Item 3.01&#160;&#160;&#160;&#160;Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">On November 2, 2022, Spectrum Pharmaceuticals, Inc. (the &#8220;Company&#8221;) received written notice (the &#8220;Notice&#8221;) from The NASDAQ Stock Market (&#8220;Nasdaq&#8221;) notifying the Company that, because the closing bid price for the Company&#8217;s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">The Notice has no immediate effect on the listing of the Company&#8217;s common stock on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 2, 2023, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to May 2, 2023. If at any time during this 180-day compliance period the closing bid price of the Company&#8217;s common stock meets these requirements, then Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">If the Company does not regain compliance by May 2, 2023 the Company may be eligible for an additional 180-day compliance period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition, the Company would be required to provide written notice to Nasdaq of its intent to cure the minimum bid price deficiency during this second compliance period by effecting a reverse stock split, if necessary.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company&#8217;s common stock will be subject to delisting. The Company would then be entitled to appeal the Nasdaq staff&#8217;s determination to a Nasdaq Listing Qualifications Panel and request a hearing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:104%">The Company intends to monitor the closing bid price of the Company&#8217;s common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. No determination regarding the Company&#8217;s response has been made at this time. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing criteria.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iea2e71bb5fc94cb4adc88cbd9eb39a3d_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:137.25pt;padding-right:137.25pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">SPECTRUM PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">November 7, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">/s/ Keith M. McGahan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Keith M. McGahan <br/>Executive Vice President, Chief Legal Officer and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "sppi-20221102.htm", "description": "8-K", "secsgml_size_bytes": 33689}]
{"company-data": {"conformed-name": "SPECTRUM PHARMACEUTICALS INC", "cik": "0000831547", "assigned-sic": "2834", "irs-number": "930979187", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35006", "film-number": "221366686"}, "business-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052", "phone": "702-835-6300"}, "mail-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052"}, "former-company": [{"former-conformed-name": "NEOTHERAPEUTICS INC", "date-changed": "19960819"}, {"former-conformed-name": "AMERICUS FUNDING CORP", "date-changed": "19920703"}]}
sppi-20221102
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 2, 2022
SPECTRUM PHARMACEUTICALS INC
(Exact name of registrant as specified in its charter)
Delaware
001-35006
93-0979187
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
Pilot House-Lewis Wharf Atlantic Ave
6th Floor
Boston
MA
02110
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
617
)
586-3900
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
SPPI
The NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 3.01    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 2, 2022, Spectrum Pharmaceuticals, Inc. (the "Company") received written notice (the "Notice") from The NASDAQ Stock Market ("Nasdaq") notifying the Company that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the "Minimum Bid Price Requirement"), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days.
The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 2, 2023, to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to May 2, 2023. If at any time during this 180-day compliance period the closing bid price of the Company's common stock meets these requirements, then Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed.
If the Company does not regain compliance by May 2, 2023 the Company may be eligible for an additional 180-day compliance period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition, the Company would be required to provide written notice to Nasdaq of its intent to cure the minimum bid price deficiency during this second compliance period by effecting a reverse stock split, if necessary.
If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal the Nasdaq staff's determination to a Nasdaq Listing Qualifications Panel and request a hearing.
The Company intends to monitor the closing bid price of the Company's common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement. No determination regarding the Company's response has been made at this time. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing criteria.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPECTRUM PHARMACEUTICALS, INC.
Date:
November 7, 2022
By:
/s/ Keith M. McGahan
Keith M. McGahan
Executive Vice President, Chief Legal Officer and Secretary